Acrp Ccra Exam Prep 2026 – Practice Questions, Verified Answers & Detailed Rationales

ACRP CCRA EXAM PREP 2026 – PRACTICE
QUESTIONS, VERIFIED ANSWERS &
DETAILED RATIONALES
ACRP CCRA EXAM PREP 2026 – PRACTICE QUESTIONS, VERIFIED ANSWERS &
DETAILED RATIONALES

====================================================================
============

DOCUMENT OVERVIEW:

• This comprehensive 200-question study material is designed to thoroughly
prepare you for the ACRP CCRA certification exam through verified answers and
detailed rationales that reinforce clinical research fundamentals.

• Use this resource by studying 20-30 questions daily, focusing on understanding
the rationale behind each correct answer rather than memorizing, and review weak
topic areas using the organized question structure.

====================================================================
============

QUESTION 1:

A Clinical Research Associate (CRA) is conducting a source data verification at
a study site. During the review, the CRA notices that the informed consent
form (ICF) was signed after the patient received the first dose of study
medication. What is the most appropriate action for the CRA to take?

A) Document this observation and continue the monitoring visit as planned

B) Immediately report this serious violation to the Sponsor's Regulatory Affairs
department

C) Ask the site staff to backdate the ICF signature to before the first dose

D) Inform the patient verbally and proceed with the study

E) Allow the site one week to correct the ICF documentation

CORRECT ANSWER: B) Immediately report this serious violation to the
Sponsor's Regulatory Affairs department

,RATIONALE: The ICF must be signed BEFORE any study procedures or
administration of investigational product. This is a critical GCP requirement and a
fundamental ethical principle to ensure informed consent is obtained prior to study
participation. Backdating documents is falsification of records. This violation must
be reported immediately to the Sponsor as it affects patient safety, informed
consent validity, and regulatory compliance. The CRA has a duty to identify and
escalate such issues promptly.

====================================================================
============

QUESTION 2:

During a monitoring visit, a CRA identifies that a patient's eligibility was not
properly verified before enrollment. The patient does not meet one of the key
inclusion criteria. What is the most appropriate next step?

A) Continue the patient in the study but document the eligibility issue

B) Report the protocol deviation to the Sponsor immediately and determine if the
patient should be withdrawn

C) Allow the patient to complete the study before addressing the eligibility issue

D) Discuss with the site investigator but do not involve the Sponsor

E) Retroactively amend the patient's eligibility assessment

CORRECT ANSWER: B) Report the protocol deviation to the Sponsor
immediately and determine if the patient should be withdrawn

RATIONALE: Protocol deviations, especially those involving patient eligibility, must
be reported to the Sponsor immediately. Ineligible patients should not continue in
the study as they compromise data integrity and patient safety. The Sponsor must
assess whether the patient should be withdrawn and whether any data collected is
valid. This is a fundamental quality and compliance requirement in clinical research.

====================================================================
============

QUESTION 3:

,What is the primary purpose of the ICF in clinical research?

A) To protect the research institution from liability

B) To ensure the patient understands the study and voluntarily agrees to
participate

C) To meet FDA regulatory requirements only

D) To document that the patient was present at the visit

E) To provide the Sponsor with medical history information

CORRECT ANSWER: B) To ensure the patient understands the study and
voluntarily agrees to participate

RATIONALE: The informed consent form is fundamentally an ethical and legal
document designed to ensure that potential participants understand the purpose,
procedures, risks, and benefits of the study before agreeing to participate. This
protects patient autonomy and rights. While it does protect institutions and meet
regulatory requirements, the primary purpose is ensuring informed, voluntary
consent from the participant.

====================================================================
============

QUESTION 4:

A CRA discovers that source documents at a study site are missing entries for
several adverse events. What type of data quality issue is this considered?

A) Accuracy issue

B) Completeness issue

C) Consistency issue

D) Timeliness issue

E) Traceability issue

CORRECT ANSWER: B) Completeness issue

, RATIONALE: Completeness refers to whether all required data have been collected
and recorded. Missing adverse event entries represent a completeness gap in the
source documentation. While accuracy, consistency, and timeliness are also
important data quality dimensions, missing information is specifically a
completeness problem. Traceability refers to ability to track data changes and audit
trails.

====================================================================
============

QUESTION 5:

Under GCP guidelines, what is the minimum time period during which
essential trial documents must be retained after the end of the trial?

A) 1 year after study completion

B) 2 years after study completion

C) 3 years after study completion

D) 5 years after study completion

E) 10 years after study completion

CORRECT ANSWER: B) 2 years after study completion

RATIONALE: According to ICH GCP E6(R2), essential trial documents must be
retained for at least 2 years after the completion or formal termination of the
clinical trial. Some countries may require longer retention periods, and this should
be verified based on local regulations. This timeframe allows for regulatory
inspections, audits, and potential queries about trial data.

====================================================================
============

QUESTION 6:

A patient randomized to a study treatment experiences a serious adverse
event (SAE). According to GCP, how quickly should this be reported to the
Sponsor?